초록

The present invention features a formulation from the Indian mulberry plant (Morinda citrifolia ) comprising Morinda citrifolia fruit juice, Morinda citrifolia oil, quercetin, Morinda citrifolia puree juice and Morinda citrifolia dietary fiber treating Candidiasis.

대표청구항 ▼

What is claimed and desired to be secured by Letters Patent is: 1. A formulation for treating Candidiasis comprising: processed Morinda citrifolia juice; between about 0.1-30 percent by weight of the formulation of Morinda citrifolia oil; and between about 0.1 and 20 percent by weight of the formul

What is claimed and desired to be secured by Letters Patent is: 1. A formulation for treating Candidiasis comprising: processed Morinda citrifolia juice; between about 0.1-30 percent by weight of the formulation of Morinda citrifolia oil; and between about 0.1 and 20 percent by weight of the formulation of Quercetin. 2. The formulation of claim 1, wherein said processed Morinda citrifolia product comprises between about 50-99.8 by weight of Morinda citrifolia fruit juice. 3. The formulation of claim 1, wherein said formulation further comprises Morinda citrifolia puree juice. 4. The formulation of claim 1, wherein said further comprises Morinda citrifolia puree juice concentrate. 5. The formulation of claim 1, wherein said formulation further comprises Morinda citrifolia fruit juice concentrate. 6. The formulation of claim 1, wherein said formulation further comprises Morinda citrifolia dietary fiber. 7. The formulation of claim 1, wherein said Quercetin is present in an amount between about 0.1 and 10 percent by weight of the formulation. 8. The formulation of claim 7, wherein said formulation further comprises Rutin. 9. The formulation of claim 8, wherein said Rutin is present in an amount between about 0.1 and 10 percent by weight of the formulation. 10. The formulation of claim 1 wherein said formulation is in a form suitable for oral administration. 11. The formulation of claim 1 wherein said formulation is in a form suitable for transdermal administration. 12. The formulation of claim 1, wherein said formulation is in a form suitable for intravenous administration. 13. The formulation of claim 1, wherein said formulation is in a form suitable for systemic administration.